# ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

> **NCT07090330** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Oruka Therapeutics, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** ORKA-001 Induction Dose
- **OTHER:** Placebo
- **DRUG:** ORKA-001 Maintenance Dose

## Key facts

- **NCT ID:** NCT07090330
- **Lead sponsor:** Oruka Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2026-04
- **Final completion:** 2027-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090330, "ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07090330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*